Body mass index and prostate specific antigen levels in Jamaican men

West Indian Medical Journal

Volumn 60, Issue 3, 2011, Pages 316-321

  Tulloch Reid, M K ^a   Aiken, W D ^a   Morrison, B F ^a   Tulloch, T ^a   Mayhew, R ^a   Wan, R L ^b   Bennett, F I ^a   Coard, K C ^a   Jackson, M D ^a  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

^b Kingston Public Hospital   (Jamaica)

Author keywords

Black; Caribbean; Obesity; Prostate cancer; PSA

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CANCER GRADING; CONTROLLED STUDY; DIET; HUMAN; HUMAN TISSUE; JAMAICA; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; OBESITY; PROSTATE BIOPSY; PROSTATE CANCER; QUESTIONNAIRE; SEXUAL BEHAVIOR; SMOKING; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; PROSTATE TUMOR; REGRESSION ANALYSIS;

ADULT; AGED; BODY MASS INDEX; CASE-CONTROL STUDIES; HUMANS; JAMAICA; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS;

EID: 84856250525     PISSN: 00433144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Gibson TN, Hanchard B, Waugh N, McNaughton D. Age-specific incidence of cancer in Kingston and St Andrew, Jamaica, 2003-2007. West Indian Med J 2010; 59: 456-64.
2. Blake G, Hanchard B, Mitchell K, Simpson D, Waugh N, Wolff C et al. Jamaica cancer mortality statistics, 1999. West Indian Med J 2002; 51: 64-7.
3. Ando R, Nagaya T, Hashimoto Y, Suzuki S, Itoh Y, Umemoto Y et al. Inverse relationship between obesity and serum prostate-specific antigen level in healthy Japanese men: a hospital-based cross-sectional survey, 2004-2006. Urology 2008; 72: 561-5.
4. Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandez J, Basler J et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005; 103: 1092-5.
5. Fowke JH, Signorello LB, Chang SS, Matthews CE, Buchowski MS, Cookson MS et al. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer 2006; 107: 2361-7.
6. Price MM, Hamilton RJ, Robertson CN, ButtsMC, Freedland SJ. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic. Urology 2008; 71: 787-91.
7. Rundle A, Neugut AI. Obesity and screening PSA levels among men undergoing an annual physical exam. Prostate 2008; 68: 373-80.
8. Ochiai A, Fritsche HA, Babaian RJ. Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer. Urology 2005; 66: 819-23.
9. Kim YJ, Han BK, Hong SK, Byun SS, Kim WJ, Lee SE. Body mass index influences prostate-specific antigen in men younger than 60 years of age. Int J Urol 2007; 14: 1009-12.
10. Werny DM, Thompson T, Saraiya M, Freedman D, Kottiri BJ, German RR et al. Obesity is negatively associated with prostate-specific antigen in US men, 2001-2004. Cancer Epidemiol Biomarkers Prev 2007; 16: 70-6.
11. Beebe-Dimmer JL, Faerber GJ, Morgenstern H, Werny D, Wojno K, Halstead-Nussloch B et al. Body composition and serum prostatespecific antigen: review and findings from Flint Men's Health Study. Urology 2008; 71: 554-60.
12. Joseph MA,Wei JT, Harlow SD, Cooney KA, Dunn RL, Jaffe CA et al. Relationship of serum sex-steroid hormones and prostate volume in African American men. Prostate 2002; 53: 322-9.
13. Farnsworth WE. Estrogen in the etiopathogenesis of BPH. Prostate 1999; 41: 263-74.
14. Chang IH,Ahn SH, Han JH, Kim TH, KimYS,Myung SC. The clinical significance in healthy men of the association between obesity related plasma hemodilution and tumor marker concentration. J Urol 2009; 181: 567-72.
15. Mener DJ, Cambio A, Stoddard DG, Martin BA, Palapattu GS. The impact of HMG-CoA reductase therapy on serum PSA. Prostate 2010; 70: 608-15.
16. Mondul AM, Selvin E, De Marzo AM, Freedland SJ, Platz EA. Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004. Cancer Causes Control 2010; 21: 671-8.
17. Wilks R, Yonger N, Tulloch-Reid M, McFarlane S, Francis D. Jamaica Health and Lifestyle Survey [Internet]. Findings at a Glance; 2007-8. Epidemiology Research Unit, TMRI. Last accessed 11-2-2010. Available from: http://www.uwicentre.edu.jm/reports/health/JHLSII_ final_may09.pdf
18. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i-xii, 1-253.
19. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966; 50: 125-8.
20. Skolarus TA, Wolin KY, Grubb RL III. The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer. Nat Clin Pract Urol 2007; 4: 605-14.
21. Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298: 2275-80.
22. Gapstur SM, Gann PH, Kopp P, Colangelo L, Longcope C, Liu K. Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epidemiol Biomarkers Prev 2002; 11: 1041-7.
23. Grubb RL III, Black A, Izmirlian G, Hickey TP, Pinsky PF, Mabie JE et al. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev 2009; 18: 748-51.